Re: Japanese publication response from IR

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Japanese publication response from IR

in response to

Japanese publication response from IR

Nextblockbuster

posted on Nov 01, 2016 02:09PM

I disagree with Clayton's response. Slide 15 suggests that the ZEN-3694 trial in combination with enzalutamide should being dosing H2 2016. The bar representing this trial starts at the Q3/Q4 junction of 2016 and goes until the Q3/Q4 junction of 2017.